This trial is evaluating whether Nintedanib will improve 1 primary outcome in patients with Cancer of Pancreas. Measurement will happen over the course of Each 28 day cycle for 2 years.
This trial requires 20 total participants across 2 different treatment groups
This trial involves 2 different treatments. Nintedanib is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
The data suggest common treatments and procedures: 1. Chemotherapy; 2. Surgery; 3. Radiation; 4. Supportive care. The most likely reason for common treatments might be the fact, that they are considered standard treatment with the best cure outcomes, even if there is some degree of toxicity.
Cancers of pancreatic ductal (pancreatic adenocarcinoma and intraductal mucinous adenocarcinoma ) and pancreatic head (both pancreatic adenocarcinoma and squamous cell carcinoma or mixed type of adenocarcinoma) seem to have no possibility of curative treatment as of 2014. And we cannot make the curative treatment for cancer of pancreatic ductal.
The combination of obesity, a family history of pancreatic cancer, type 2 diabetes, and smoking is the leading risk factor for developing pancreatic cancer; the genetic and environmental factors mentioned here can only be implemented into prediction models.
Pancreatic cancer often presents with weight loss, jaundice and pain in the upper abdomen. The overall five-year survival rate for pancreatic cancer is between 9% and 29%. Tumours that have produced symptoms of jaundice and pancreatobiliary pain can often be successfully surgically removed; however, treatment of symptoms caused by malignancy is less successful. More importantly, patients with pancreatic cancer suffer from malnutrition and often have poor oral intakes which can lead to malnutrition. Therefore, proper nutritional care is essential to aid survival.
About 80,000 cases of [pancreatic cancer](https://www.withpower.com/clinical-trials/pancreatic-cancer) are diagnosed a year in the United States. This makes it the 10th most common type of cancer, and the 2nd most common cause of death in US men over the age of 45.
Nintedanib was generally well-tolerated across all types of cancer. With the number of deaths that occur after stopping treatment, it is important for patients to carefully report side effects to their treating physician. The most common common side effects are diarrhea, headaches, rash, nausea, insomnia, and fatigue. Treatments to manage these side effects should be provided as necessary.
The addition of nintedanib (vs placebo) in pancreatic cancers did not result in a greater percentage of objective responses or prolongation of progression-free survival compared with placebo. Nintedanib is not a more active drug option in patients with pancreatic cancer. (Int J Gastrop., 2016;16:119-132).
[If you are looking to join a pancreatic cancer clinical trial, Power can help you search recent trials by condition, treatment, or location.] Pancreatic cancer was first described in 1843 by German pathologist Richard von Stilling (1800-1879). Today, pancreatic cancer is the third most common cause of cancer-related deaths in the UK (13,100 cases were diagnosed in 2007). If you have had a pancreaticoduodenectomy (surgery to remove part of your small intestine and the pancreas), you should be considered a potential pancreatic cancer patient.
The study demonstrates that nintedanib has clinical therapeutic value at inhibiting tumor growth and prolonging PFS in the treatment of advanced non-small cell [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer)(NSCLC), gastric cancer and in a number of other tumors, which will help identify and develop drug candidates for further evaluation in cancer.
All the patients have been prescribed nintedanib and have a disease course of some years. It can be concluded that trials with different chemotherapy agents for advanced pancreatic cancer are necessary. Results from a recent clinical trial should not preclude the use of a chemotherapeutic agent (like nintedanib) as a treatment of last resort, after repeated failures of drugs like gemcitabine, irinotecan, pemetrexed, or erlotinib.
The overall five-year survival rate with aggressive surgery was about 90%; the survival for Stage IV patients may be significantly improved with a higher percentage of unresectable patients.